BioSpace News Archive

Enhertu Granted Priority Review in the US for Patients With HER2-Positive Metastatic Breast Cancer Treated With a Prior Anti-HER2-Based Regimen.

CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that the company’s Chief Technology Officer, Dr. Mariola Fotin-Mleczek, will resign from CureVac effective January 31, 2022.

Health to U (“H2U”) Corporation, an industry-leader in connected healthcare technology and provider of digital health and wellbeing platforms, is ringing in the New Year by announcing the close of a US$8 million round of funding, led by SHARP and Foxconn Technology.

RODO Medical and The Aurum Group have entered a strategic partnership to launch Rodo Digital Prosthetics (RDP) in the U.S. RDP will be a new dental laboratory combining RODO’s proprietary technologies with Aurum’s Core3dcentres.

Pfizer Canada announced today that Health Canada has authorized the use of PAXLOVID™ (nirmatrelvir tablets and ritonavir tablets) for the treatment of mild-to-moderate COVID-19 in adults (18 years of age and older) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.

. Upon review, the Company determined that a third party, which was not engaged by the Company or any of its officers, directors, controlling shareholders or any third-party service providers distributed promotional emails.

Masimo (NASDAQ: MASI) today announced the findings of an abstract presented last Saturday at the Society for Technology in Anesthesia 2022 Annual Meeting, which reviewed retrospective pulse oximetry data and concluded that there was no clinically significant bias based on ethnicity for black and white volunteer subjects monitored with Masimo SET® pulse oximetry and RD SET® sensors.

ReviR Therapeutics, a South San Francisco based biopharmaceutical company, completed a Pre-A financing round with ~$20M.

Today, the Honourable Filomena Tassi, Minister of Public Services and Procurement, announced that the Government of Canada has received an initial shipment of 30,400 treatment courses of Pfizer’s COVID-19 oral antiviral treatment, PAXLOVIDTM, with 120,000 more expected to be delivered between now and the end of March.

MedX Health Corp., a global leader in teledermatology, is pleased to announce that MedX’s leading-edge DermSecure® screening platform services are being offered in Empower’s The Medi-Collective locations across Ontario, Canada.